Physician profile
Edward Charles Osterberg
NPI 1477795458
$33,138.64
in general payments reported to CMS, 2019-2025
31 companies · $14K in 2025
The $14K reported for 2025 was more than what 95% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,690 · 2020: $162 · 2021: $34.86 · 2022: $820 · 2023: $1,596 · 2024: $12K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Education: $7,255 · Food and Beverage: $5,167 · Travel and Lodging: $2,810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,200.00 |
| Education | $7,254.85 |
| Food and Beverage | $5,166.98 |
| Travel and Lodging | $2,809.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $14,597.58 | 2019-2024 | |
| Biotissue Holdings INC. | $13,639.23 | 2022-2025 | |
| Endo Pharmaceuticals INC. | $679.54 | 2020-2024 | Xiaflex, Aveed |
| Boston Scientific Corporation | $627.21 | 2020-2025 | Ams 700, Ams 800 Artificial Urinary Sphincter, Lithovue |
| Coloplast Corp | $481.55 | 2021-2025 | Titan, Speedicath |
| Abbvie INC. | $475.18 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $303.91 | 2024-2025 | Adstiladrin |
| Janssen Biotech, INC. | $291.05 | 2024-2025 | Erleada, Balversa |
| Pfizer INC. | $286.10 | 2023-2025 | |
| Procept Biorobotics Corporation | $279.85 | 2024-2025 | Aquabeam System, Aquabeam Robotic System |
| C. R. Bard, INC. & Subsidiaries | $261.33 | 2022 | |
| Endo USA, INC. | $195.08 | 2024-2025 | Xiaflex, Aveed |
| Sumitomo Pharma America, INC. | $179.32 | 2024-2025 | Gemtesa, Orgovyx |
| Olympus America INC. | $138.62 | 2024-2025 | Itind System |
| Dendreon Pharmaceuticals LLC | $95.46 | 2024-2025 | Provenge |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $84.60 | 2025 | |
| Teleflex LLC | $69.13 | 2024-2025 | Barrigel, Urolift |
| Progenics Pharmaceuticals, INC. | $64.95 | 2023 | Pylarify |
| Sun Pharmaceutical Industries INC. | $60.37 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $55.59 | 2024 | Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $41.25 | 2025 | |
| Antares Pharma, INC. | $36.34 | 2024 | Xyosted |
| 180 Medical, INC. | $28.49 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $27.82 | 2024 | Lynparza |
| Myriad Genetic Laboratories, INC. | $24.48 | 2024 | Prolaris |
| Immunitybio, INC. | $23.96 | 2025 | |
| Urogen Pharma, INC. | $23.85 | 2025 | |
| Kerecis Limited | $22.75 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Mimedx Group, INC. | $16.70 | 2024 | |
| Telix Pharmaceuticals | $15.94 | 2024 | Illuccix |
| Dentsply Ih INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Osterberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.